###### Significance Statement

This study is the first to our knowledge to connect the downregulation of MCHR1 mRNA in the brains of schizophrenia patients to a causal link between the germline MCHR1 deletion in mice and social deficits as well as deficits in sensorimotor gating and multiple cognitive tasks that resemble schizophrenia symptoms.

Here we show that MCHR1 mRNA levels are significantly lower in the prefrontal cortex of subjects with schizophrenia using a large sample of 901 subjects. There is a widespread cortical expression of MCHR1, increasing after birth and then showing a strong decrease of expression with aging. There is also a decreased expression of MCHR1 in the PFC from female compared with male brains. In human brain we showed single nuclei coexpression of SST and MCHR1 were enriched above sparse expression in 90% of nuclei examined.

We also showed that disruptions in the MCH system in the mouse brain by complete deletion of MCHR1 and by conditional ablation of MCH expressing neurons using a Cre-inducible diphtheria toxin (iDTR) system led to behavioral abnormalities mimicking schizophrenia-like phenotypes. Our study indicates that the disruption of the MCH system interferes with neurodevelopmental processes, which may contribute to the pathogenesis of schizophrenia, suggesting the MCH as a therapeutic target for early prevention and/or treatment of schizophrenia.

Background {#s1}
==========

The hypothalamic neuropeptide melanin-concentrating hormone (MCH) is a cyclic peptide originally discovered in fish to induce paling of the skin. In mammals, MCH is expressed almost exclusively in the lateral hypothalamus (LH) and zona incerta (ZI) but projects throughout the central nervous system ([@CIT0007]), indicating that it has a broad range of functions. The MCH system has been implicated as a regulator of energy homeostasis and food intake ([@CIT0042]; [@CIT0045]) but also of sleep, stress, mood, aggression, reward, and cognition ([@CIT0046], [@CIT0047]; [@CIT0013], [@CIT0014]; [@CIT0008]; [@CIT0017]; [@CIT0058]).

MCH exerts its action through interacting with 1 G protein-coupled receptor, MCHR1 ([@CIT0006]; [@CIT0012]; [@CIT0048], [@CIT0048]; [@CIT0056]), which has a widespread distribution in the brain. The abundance of MCHR1 in the frontal cortex, amygdala, nucleus accumbens, septum, and hippocampus ([@CIT0023]; [@CIT0050]) provides an anatomical basis for an MCH role in the modulation of emotional and cognitive functions ([@CIT0001]). MCHR1 sites in the hippocampus, which controls spatial memory, have been shown to modulate cellular mechanisms underlying learning, such as N-methyl-D-aspartate receptor (NMDA) receptor-dependent production of nitric oxide ([@CIT0060]) and facilitation of synaptic transmission ([@CIT0033]; [@CIT0059]). MCH was shown to have a facilitatory effect on CA1 glutamatergic synaptic transmission and long-term synaptic plasticity ([@CIT0039]). This effect was supported by the fact that the long-term synaptic depression and long-term synaptic potentiation, 2 cellular models of learning and memory, are strongly impaired in MCHR1 knockout mice ([@CIT0039]). Also, AMPA and NMDA receptors are downregulated in the mutant mice compared with their controls ([@CIT0001]; [@CIT0039]; [@CIT0054]).

The largest genome-wide association study (GWAS) to date of schizophrenia (SZ) has shown a credible locus harboring the MCHR1 gene on chr:22q13.2 ([@CIT0040]). Candidate gene studies have revealed nominal associations between single nucleotide polymorphisms (SNPs) located in the MCHR1 gene and schizophrenia ([@CIT0055]; [@CIT0015]). There are no reported associations of SZ and PMCH to our knowledge.

Human genetic association studies and the findings of animal anatomical, physiological, and pharmacological studies led us to hypothesize a possible causal effect of MCH system dysfunction in the development of schizophrenia. Therefore, the primary aims of this study were to determine whether MCHR1 and PMCH mRNA levels are altered in the brains of schizophrenia patients and to investigate whether the germline deletion of the MCH receptor (MCHR1 KO) or the conditional ablation of MCH neurons (MCH cKO) produces behavioral responses in mice that mimic symptoms of schizophrenia.

Methods {#s2}
=======

Human Study of MCH System Expression {#s3}
------------------------------------

### PsychEncode and CommonMind Studies {#s4}

PsychEncode (Brain-GVEX study) and CommonMind RNA-Seq datasets were jointly analyzed using data directly downloaded from Synapse.org (Project PI, MPV). Only controls and patients diagnosed with SZ were included, resulting in a combined total of 901 dorsolateral prefrontal cortex samples (544 controls, 357 SZ) ([Table 1](#T1){ref-type="table"}). The RNA-Seq data were processed by TruSeq adapters removed using cutadapt, transcript abundances were quantified using Salmon ([@CIT0041]) and the number of reads summarized at the gene level using Gencode version 29. Genes were required to be expressed above a threshold of 5 counts per million (CPM) in at least 10 patients, resulting in 18 595 genes for the combined dataset. Analysis of differential gene expression was performed using limma/voom by fitting a weighted least squares model to log-transformed CPM values ([@CIT0027]). In addition to psychiatric diagnosis, the covariates included in the model were age (binned at ≥90), sex, postmortem interval, RNA Integrity Number, and brain bank. *P* values were based on a moderated *t* statistic, and false discovery rates for multiple testing were calculated using the Benjamini-Hochberg method.

###### 

The analysis of MCHR1 in the combined dataset from PsychEncode and CommonMind included a total of 901 subjects

  ---------------------- -----
  Control                544
  F                      213
   CMC MSSM              79
   CMC Penn              19
   CMC Pitt              24
   PENC BSHRI            76
   PEC SMRI Array        9
   PEC SMRI Consortium   5
   PEC SMRI Extra        1
  M                      331
   CMC MSSM              85
   CMC Penn              18
   CMC Pitt              60
   PENC BSHRI            108
   PEC SMRI Array        25
   PEC SMRI Consortium   8
   PEC SMRI Extra        8
   PEC SMRI New          19
  SCZ                    357
  F                      122
   CMC MSSM              47
   CMC Penn              35
   CMC Pitt              13
   PEC SMRI Array        8
   PEC SMRI Consortium   3
   PEC SMRI Extra        8
   PEC SMRI New          8
  M                      235
   CMC MSSM              101
   CMC Penn              23
   CMC Pitt              44
   PEC SMRI Array        26
   PEC SMRI Consortium   8
   PEC SMRI Extra        23
   PEC SMRI New          10
  Grand Total            901
  ---------------------- -----

CMC, Common Mind Consortium; F, Female; M, Male; PEC, PsychENCODE Consortium; SMRI, Stanley Medical Research Institute; BSHRI, Banner Sun Health Research Institute.

Details on PsychEncode and CommonMind collections can be found at <https://www.synapse.org/#!Synapse:syn4590909>.

### Capstone Collection {#s5}

To obtain cross-sectional expression of MCHR1 from prenatal to the elderly brain, we examined data available from Capstone collection ([@CIT0018]). The developmental dataset modeled differential expression across age in 320 control subjects across the lifespan from prenatal to over 90 years of age (data available to MPV through access at <https://www.synapse.org/>\#!Synapse:syn12080241). We examined the expression of MCHR1 across the lifespan using binned data.

### Allen Institute For Brain Science {#s6}

Single-nuclei exon-mapping read counts for 15 928 cells from the middle temporal gyrus were obtained from the Allen Institute's web portal (<https://celltypes.brain-map.org/rnaseq>), and differential gene expression tests between the 4 major cell classes were performed on log-transformed CPM values using nonparametric statistics due to the majority of nuclei showing zero expression level of MCHR1.

Animal Study of MCH System {#s7}
--------------------------

All experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of California, Irvine and were performed in compliance with national and institutional guidelines for the care and use of laboratory animals.

### MCHR1 Knockout Mice {#s8}

Ten- to 12-week-old male and female wild-type and MCHR1 knockout (MCHR1 KO) mice were used for the behavioral experiments. MCHR1 KO mice were generated as previously described ([@CIT0030]). MCHR1 KO mice were backcrossed to a BL6 background for 9 or more generations, and then littermates were separately bred to generate the wild-type and MCHR1 KO mice.

### MCH Conditional Knockout (MCH cKO) Mice {#s9}

PmchCre/+;iDTR/^+^ mice were generated as described previously ([@CIT0004]). Briefly, (Pmch-Cre) mice (Jackson Laboratories, Bar Harbor, ME) that express Cre-recombinase (Cre) under the MCH promoter ([@CIT0026]) were crossed with homozygous inducible diphtheria toxin receptor iDTR/^+^ mice (from Dr Satchidinanda Panda and originally generated in the laboratory of Dr Ari Waisman) ([@CIT0011]; [@CIT0051]). The resulting iDTR^+^PmchCre^+^ (iDTR^+^/Cre^+^) and their control littermate iDTR^+^PmchCre^−^(iDTR^+^/Cre^−^) mice were injected twice in 4 days with the diphtheria toxin (DT) (16 µg/kg, i.p.).

Behavioral Assays {#s10}
-----------------

### Locomotion and Stereotypy Assays {#s11}

Locomotor activity and stereotypy were carried out as described previously ([@CIT0003]). Mice were placed into a 40- × 40-cm locomotion test chamber (Med Associates, Inc.) and allowed to habituate to the chamber for 30 minutes. The horizontal, vertical, and stereotypic counts were recorded for 1 hour and analyzed using Activity Monitor 5 software (Med Associates, Inc.). The animal is recorded as exhibiting stereotypy when it breaks the same beam (or set of beams) repeatedly. This typically occurs during grooming and head bobbing.

### Marble Burying {#s12}

Marble burying was carried out as described previously ([@CIT0051]). Mice were placed in a 30- × 18- × 12-cm polypropylene box containing 24 glass marbles (1.5-cm diameter) evenly spaced on the surface of 3 cm deep fresh bedding. After the end of the 30-minute sessions, which were video recorded, the number of marbles buried was counted by observers who were blind to the animal genotype or sex.

### Three-Chamber Sociability Test {#s13}

The sociability assay was carried out as described previously using the 3-chambers apparatus (manufactured by carpentry facility, University of California, Irvine, CA) that has empty wire-mesh containment cups placed in the middle of the side chambers ([@CIT0003]). The tested mice were placed in the middle chamber and allowed exploration for 5 minutes with the dividing doors closed. A control mouse was placed inside the containment cup in one of the side chambers. The dividing doors were then removed between the chambers, and the test mouse was allowed to roam freely between all chambers for a total time of 10 minutes. Tests were video-recorded and analyzed by ANY-MAZE software (Stoelting Co.). The duration of direct contacts between the subject mice with both cups was scored individually.

### Novel Object Recognition and Location-Dependent Object Recognition Assays {#s14}

The novel object recognition (NOR) and location-dependent object recognition assays were carried out as described previously ([@CIT0003]). Mice were habituated to the experimental apparatus (manufactured by carpentry facility, University of California, Irvine) for 10 min/d for 3 consecutive days. In the training phase, mice were allowed to explore 2 identical objects for 10 minutes. Twenty-four hours later, the retention test was conducted. In the NOR retention test, mice were allowed to explore 1 familiar and 1 novel object for 5 minutes. The time spent exploring the 2 objects was recorded. In location-dependent object recognition retention tests, mice were allowed to explore 1 familiar object placed in the same location as during the training phase and another familiar object placed in a novel location for 5 minutes. Time spent with objects in the 2 locations was recorded. The relative exploration time was expressed by a discrimination index: \[D.I. = (T~novel~ − T~familiar~)/ (T~novel~ + T~familiar~) × 100%\]. Tests were video recorded and analyzed by ANY-MAZE software (Stoelting Co.).

### Prepulse Inhibition (PPI) Assay {#s15}

The PPI assay was measured using the startle chambers (San Diego Instrument, Inc.) with a high-frequency loudspeaker that produced background noise of 65 dB as well as the various acoustic stimuli ([@CIT0003]). A total of 65 readings are recorded at 1-millisecond intervals beginning at the stimulus onset. Average amplitude is used as the measure of startle.

During the test, mice were placed in the startle chambers for 5 minutes acclimation with 65-dB background noise. The PPI session consisted of 5 different trials: no-stimulus trials, 3 prepulse trials, and startle trials. No-stimulus trials consist of background noise only (65 dB). Startle trials consist of a 40-millisecond-duration startle stimulus at 120 dB (p120). Prepulse trials consist of a 20-millisecond-duration prepulse at 68 dB (pp3), 71 dB (pp6), or 77 dB (pp12), a 100-millisecond inter-stimulus interval, followed by a 40-millisecond-duration startle stimulus at 120 dB. The level of PPI is calculated as a percentage score for each acoustic prepulse intensity: % PPI = 100-(\[(startle response for prepulse+pulse trials)/ (startle response for pulse-alone trials)\] × 100).

### Contextual Fear Conditioning Assay {#s16}

The Contextual Fear Conditioning Assay was carried out as previously described ([@CIT0003]). During the training session, mice were placed in the conditioning chamber (TSE Systems, Inc.) for 2.5 minutes before receiving a 0.7-mA foot shock lasting for 2 seconds. After an additional 30 seconds in the chamber, mice were returned to their home cages. Freezing behavior prior to and after the shock (pre-and post-shock sessions) was measured. Twenty-four hours after training, mice were placed back into the same chamber (same conditioned context: wallpaper with striped pattern) in the absence of shock for 5 minutes, and their freezing behavior during this period (retention session) was measured. Freezing behavior was scored as freezing (1) or not (0) within an interval of 5 seconds, and the percentage of freezing behavior was calculated as 100 × (the number of intervals of freezing/ total intervals).

Immunohistochemistry {#s17}
--------------------

### Verification of DT-Induced Ablation of MCH {#s18}

At the end of all behavioral experiments, iDTRPmchCre animals were perfused transcardially with 4% paraformaldehyde, and coronal brain sections (20 mm) through the LH were cut. The MCH-neuron ablation was verified by visualizing MCH neurons using rabbit polyclonal anti-MCH antibody (1:150 000, antibody courtesy of W. Vale, Salk Institute, La Jolla, CA) as previously described ([@CIT0051]). A goat anti-rabbit secondary antibody (1:500; ThermoFisher) was used to visualize MCH immunoreactivity.

### Data Analysis {#s19}

Animal study: GraphPadPrism (GraphPad Software, Inc.) was used for statistical analysis. Data are presented as means ± SEM. Results for the locomotor activity, stereotypic behavior, and marble burying as well as NOR and NOL assays were analyzed using Student unpaired *t* test. Social behavior, PPI, and fear conditioning data were analyzed using 2-way ANOVA followed by the Bonferroni post hoc comparison, and *P* \< .05 was considered statistically significant.

RESULTS {#s20}
=======

Human Gene Expression {#s21}
---------------------

In the combined dataset (901 total subject;, the demographics for the SZ and control groups are shown in [Table 1](#T1){ref-type="table"}), there was a significant increase in age in control subjects (68.6 y ± 19.0 SD) compared with the age of subjects with SZ (61.7 y ± 19.1 SD, *P* \< .0001) ([Table 2](#T2){ref-type="table"}). The PMI in subjects with SZ was increased compared with controls by 2-fold from 12 hours in controls to over 25 hours in subjects with SZ (*P* \< .0001) ([Table 2](#T2){ref-type="table"}). The analysis of expression for combined dataset in the PFC thus included important demographic covariates (age, sex, PMI, RNA integrity number (RIN), brain bank).

###### 

The analysis of MCHR1 in the combined dataset (901 total subjects, each group shown in [Table 1](#T1){ref-type="table"} for SZ and controls) showed a significant increase in age in control subjects and increased PMI in subjects with SZ

  Brainbank             Diagnosis   N     M     F     Age_mean       Age_sd   RIN_mean     RIN_sd   PMI_mean       PMI_sd
  --------------------- ----------- ----- ----- ----- -------------- -------- ------------ -------- -------------- --------
  PEC BSHRI             Control     184   108   76    83.05          7.80     6.96         0.93     3.03           1.86
  PEC SMRI Array        Control     34    25    9     43.82          7.35     8.08         0.50     29.47          13.05
  PEC SMRI Array        SCZ         34    26    8     42.53          8.59     7.99         0.62     31.56          15.74
  PEC SMRI Consortium   Control     13    8     5     49.62          10.56    7.62         0.94     23.46          8.93
  PEC SMRI Consortium   SCZ         11    8     3     41.82          12.46    7.25         0.70     38.36          13.95
  PEC SMRI Extra        Control     9     8     1     45.78          14.81    7.00         0.66     27.67          14.19
  PEC SMRI Extra        SCZ         31    23    8     40.84          12.02    7.09         0.75     46.42          31.46
  PEC SMRI New          Control     19    19    0     51.42          8.69     8.16         0.62     30.11          18.38
  PEC SMRI New          SCZ         18    10    8     46.00          8.92     7.66         0.80     46.39          35.25
  CMC MSSM              Control     164   85    79    73.20          16.28    7.52         0.86     10.87          7.58
  CMC MSSM              SCZ         148   101   47    72.38          12.45    7.13         0.80     23.79          15.57
  CMC Penn              Control     37    18    19    67.14          15.04    7.46         0.70     13.42          7.51
  CMC Penn              SCZ         58    23    35    78.74          11.05    7.35         0.77     13.57          7.66
  CMC Pitt              Control     84    60    24    48.19          14.06    8.52         0.45     18.97          5.38
  CMC Pitt              SCZ         57    44    13    48.11          13.03    8.17         0.63     20.04          8.42
  Total                 Control     544   331   213   68.64          19.09    7.53         0.97     12.06          11.22
  Total                 SCZ         357   235   122   61.68          18.96    7.44         0.85     25.82          19.74
  Total                             901   566   335   *P* \< .0001            *P* = .153            *P* \< .0001   

CMC, Common Mind Consortium; PEC, PsychENCODE Consortium; SMRI, Stanley Medical Research Institute; BSHRI, Banner Sun Health Research Institute.

Details on those collections can be found here: <https://www.synapse.org/#!Synapse:syn4590909>

The subjects with SZ showed a significant decrease in MCHR1 expression (*P* value = 2.9E-04 FDR-adjusted; [Table 3](#T3){ref-type="table"}), and the sex effect was parallel in both subjects with SZ and controls ([Figure 1A](#F1){ref-type="fig"}). However, the level of MCHR1 was significantly decreased in female cortical samples compared with male cortical samples (FDR *P* value = 1.6E-02; [Figure 1B](#F1){ref-type="fig"}). Further, a highly significant decline in expression of MCHR1 was found beginning in adults ([Figure 1C](#F1){ref-type="fig"}). The separate fit of age by diagnosis showed a highly significant decrease in both controls (*P* = 2.38E-35; R-squared = 0.247, adjusted R-squared = 0.246) and subjects with SZ (*P* = 1.16E-36; R-squared = 0.363, R-squared adjusted = 0.361). When the groups were combined, the *P* value remained highly significant (R-squared = .245, adjusted R-squared = 0.244, *P* value = 6.6E-57) for the fit of age and expression of MCHR1.

###### 

The combined analysis of expression in the PFC included covariates (age, sex, PMI, RIN, brain bank) and a significant decrease in MCHR1 expression was found (FDR *P* value = 2.9E-04)

  Ensemble Gene ID    Gene Symbol   Log2 difference   Average Expression (cpm)   t       *P* value   Adjusted *P* value
  ------------------- ------------- ----------------- -------------------------- ------- ----------- --------------------
  ENSG00000128285.4   MCHR1         −0.212            2.77                       −4.21   2.73E-05    2.91E-04

There is a low expression of PMCH in human cortex; therefore, data was not included in analysis.

![(A) The main effect of MCHR1 expression (least square means, y-axis) and group (x-axis) showed a significant decrease in subjects with schizophrenia (FDR *P* value = 2E-04) and the decreased expression was parallel across sex. Females showed a decreased expression of MCHR1 (FDR *P* value = 1.6E-02). F = female; M = male. (B) Violin plot of MCHR1 expression by sex, with mean ±SD superimposed for control and schizophrenia samples shown in [Table 1](#T1){ref-type="table"}. Females showed a decreased expression of MCHR1 (FDR *P* value = 1.6E-02). (C) Scatter plot for age and sex using the 901 schizophrenia and control PFC samples ([Table 1](#T1){ref-type="table"}, demographics) showing a significant age-related decrease in expression of MCHR1. Multiple R-squared = 0.2452, adjusted R-squared = 0.2443, *P* value (2-sided) *t* test for linear regression coefficient of MCHR1 expression and age of death *P* = 6.6E-57. Note that data are binned for all subjects ages \>90 years. (D) Box plot for MCHR1 expression across the lifespan. Capstone control prefrontal cortex data obtained from (<https://www.synapse.org/#!Synapse:syn12080241>). The number of subjects in each age bin is shown in the inset.](pyz051f0001){#F1}

The prenatal expression of MCHR1 was compared with postnatal expression across the lifespan ([Figure 1D](#F1){ref-type="fig"}). The data from Capstone control prefrontal cortex was plotted, and the prenatal expression was decreased compared with the pooled postnatal decades (Mann-Whitney U test, *P* = 2.52E-31). PMCH mRNA expression was too low to be reliably determined and was excluded from analysis. The peptide MCH is expressed only in the hypothalamus compared with the cortex (Allen Brain Atlas, 141-fold higher in the hypothalamus compared with cortex).

Cortical expression of MCHR1 was investigated at the resolution of single nuclei RNA-Seq using Allen Institute data. The middle temporal gyrus nuclei ([@CIT0019]) showed the highest expression of MCHR1 in GABAegic cell types compared with glutamatergic cells (*P = .*025) and non-neuronal cells (*P* = 2.40E-18; [Figure 2A](#F2){ref-type="fig"}). There was some overlap of expression with HTR2A; however, this was in only a minority of cells that had non-zero expression (data not shown). MCHR1 expression is distributed in 22 excitatory cell types, and 33 inhibitory types ([Figure 2B](#F2){ref-type="fig"}) as judged by the SEM bar remaining above zero CPM expression level. MCHR1-positive nuclei were detected in 9.1% of nuclei (1429/15 603) and exclusively in neurons ([Figure 2B](#F2){ref-type="fig"}).

![(A) Single nuclei RNA-Seq data from human medial temporal gyrus showing cell class differential expression of MCHR1 (data publicly available at the Allen Institute for Brain Science). The mean ±SEM for single nuclei RNA-Seq expression of MCHR1 is shown for 3 cell types (no-class is omitted). The GABAergic cell type showed a significantly higher expression of MCHR1 compared with glutamatergic or non-neuronal cell types shown in the inset table listing *P* values for each comparison. (B) Box plot of cell cluster by MCHR1 expression for 3 classes of nuclei. There were 1429 positive MCHR1 expressing cells of 15 603 nuclei included in this figure, thus an estimate is that about 9.1% of all cells express MCHR1 in medial temporal gyrus.](pyz051f0002){#F2}

To obtain eQTL data, we examined data available from brainseq.org ([@CIT0021]). There is a strong eQTL to MCHR1 in the first exon of MCHR1 (Benjamini-Hochberg FDR *P* = 1.04E-06); the eQTL associated SNP (rs133073, chr22:41075695:C:T) decreased expression in prefrontal cortex.

Animal Study {#s22}
------------

### Behavioral Responses in MCHR1 KO {#s23}

Based on the human results, we asked whether the germline deletion of MCHR1 produces in mice any behavioral phenotypes that are related to schizophrenia.

Both male and female MCHR1 KO mice exhibited an increase in their locomotor activities (male: *P* \< .05, female: *P* \< .01; [Figure 3A](#F3){ref-type="fig"}) as well as a greater level of stereotypic behaviors (male: *P* \< .01, female: *P* \< .05; [Figure 3B](#F3){ref-type="fig"}).

![Effect of MCHR1 germline deletion on locomotor activity, stereotypy, marble burying, and social interaction. (A) Distance mice travelled in 60 minutes of locomotion test: male: t = 3.28, *P* = .005 (n = 9 and 7 for wild type and MCHR1 KO, respectively), female: t = 2.95, *P* = .011. Unpaired student *t* test: WT vs MCHR1 KO, \**P* \< .05, \*\**P* \< .01 (n = 8 and 7 for wild-type and MCHR1 KO, respectively). (B) Stereotypic counts in 60 minutes of locomotion test: male: t = 6.858, *P* = .0001 (n = 9 and 7 for wild-type and MCHR1 KO, respectively), female: t = 2.96, *P* \< =  .011. Unpaired student *t* test: wild type vs MCHR1 KO,\**P* \< .05, \*\*\**P* \< .001 (n = 8 and 7 for wild type and MCHR1 KO, respectively). (C) Number of marbles buried in 30 minutes: male: t = 5.41, *P* \< .001, female: t = 0.0, *P* = 1.00. Unpaired student *t* test wild type vs MCHR1 KO, \*\*\**P* \< .001 (n = 8). (D) Male: Time mice spent interacting with empty cup and control mice in social interaction test: 2-way ANOVA, genotype effect: F~1,38~ = 0.21, *P* = .65, genotype effect × cup interaction F~1,38~ = 6.783, *P* = .01. Bonferroni post hoc test: empty cup vs unfamiliar mouse, wild type: t = 4.08, *P* \< .001, KO: t = 0.51, *P* \> .05.\*\*\**P* \< .001 (n = 10 and 11 for wild type and MCHR1 KO, respectively). (E) Female: Time mice spent interacting with empty cup and control mice in social interaction test: 2-way ANOVA, genotype effect: F~1,46~ = 0.6378, *P* = .43, genotype effect × cup interaction: F~1,46~ = 5.2, *P* = .027. Bonferroni post hoc test: empty cup vs unfamiliar mouse, wild type: t = 2.387, *P* \< .01, KO: t = 1.72, *P* \> .05. \*\**P* \< .01 (n = 13 and 12 for wild type and MCHR1 KO, respectively).](pyz051f0003){#F3}

In the marble burying assay, as expected in light of our recent publication ([@CIT0051]), male MCHR1 KO mice buried more marbles than the wild-type mice (*P* \< .001; [Figure 3C](#F3){ref-type="fig"}), indicating an increase in repetitive behavior. Female MCHR1 KO mice, however, buried a number of marbles comparable with the wild-type mice (*P* \> .05; [Figure 3C](#F3){ref-type="fig"}).

In the social interaction assay, male and female wild-type mice displayed more interaction with the unfamiliar mice than the empty cup (*P* \< .001 and *P* \< .01 for male and female mice, respectively; [Figure 3D](#F3){ref-type="fig"}). However, the times that male and female MCHR1 KO mice spent with the empty cup and with the unfamiliar mouse were not significantly different (*P* \> .05; [Figure 3D](#F3){ref-type="fig"}), indicating social deficits in these animals.

The MCHR1 KO male mice exhibited a significant decrease in PPI ratio compared with the wild-type males (*P* \< .05; [Figure 4A](#F4){ref-type="fig"}), suggesting an impairment in sensorimotor gating function. MCHR1 deletion produced a decrease in PPI in female mice (2-way ANOVA, genotype effect \[F~1,55~ = 6.8, *P* = .01\]; prepulse intensity effect \[F~1,55~ = 20.66, *P* \< .0001\]); however, Bonferroni test revealed no significant difference in PPI values between MCHR1 KO and wild-type mice at any decible intensity (*P* \> .05; [Figure 4B](#F4){ref-type="fig"}).

![Effect of MCHR1 germline ablation on prepulse inhibition and different types of memory. (A) Prepulse inhibition ratio in male: 2-way ANOVA, genotype effect (F~1,48~ = 14.55, *P* = .0004), prepulse intensity effect (F~3,48~ = 6.27, P = .001) and genotype x prepulse intensity (F~3,48~ = 0.447, *P* = .72) followed by Bonferroni post hoc test: WT vs KO, \**P* \< .05 (n = 7). (B) Prepulse inhibition ratio in female, 2-way ANOVA, genotype effect (F~1,56~ = 6.8, *P* = .006), prepulse intensity effect (F~3,56~ = 20.66, *P* \< .0001), and genotype × prepulse intensity (F~3,56~ = 0.067, *P* = .98) followed by Bonferroni post hoc test: wild type vs KO, *P* \> .05 (n = 8). (C) Discrimination index in the NOR assay: male: t = 12.83, *P* = .0001. Unpaired student *t* test: wild type vs MCHR1 KO, \*\*\* *P* \< .001 (n = 7 and 6 for wild type and MCHR1 KO, respectively), female: t = 3.02, *P* = .007. Unpaired student *t* test: wild type vs MCHR1 KO, \*\*\* *P* \< .001 (n = 12 and 10 for wild type and MCHR1 KO, respectively). (D) Discrimination index in the location-dependent object recognition assay: male: t = 0.28, *P* = .178, Unpaired student t test: WT vs MCHR1 KO (n = 8), female: t = 2.65, *P* = .0.015; Unpaired student *t* test: wild type vs MCHR1 KO, \**P* \< .05 (n = 12). (E) Male: Percentage of the freezing behavior in contextual fear conditioning assay (n = 8). Training/Conditioning: 2-way ANOVA, genotype effect (F~1,28~ = 0.2789, *P* = .6), stage effect (F~1,28~ = 72.20, *P* \< .0001), test: unpaired *t* test (t = 2.8, *P* = .012), WT vs KO: \**P* \< .05. (F) Female: Percentage of the freezing behavior in contextual fear conditioning assay (n = 9). Training/Conditioning: 2-way ANOVA, genotype effect (F~1,32~ = 0.0009, *P* = .97), stage effect (F~1,32~ = 41.79, *P* \< .0001), Test: Unpaired *t* test (t = 3.6, *P = .*002), \*\**P* \< .01.](pyz051f0004){#F4}

In the novel object recognition assay, which measures neutral memory, both male and female wild-type mice spent more time exploring the new object. However, MCHR1 KO mice failed to recognize the old object vs the novel object 24 hours after the initial presentation of the training objects (*P* \< .001 and *P* \< .01 respectively for discrimination index in male and female MCHR1 KO compared with wild-type) ([Figure 4C](#F4){ref-type="fig"}). Similar results were found in the novel location recognition assay, which measures spatial memory. The female MCHR1 KO group displayed a deficit in discriminating the objects in the old and new location and displayed lower discrimination index compared with the wild-type female mice (*P* \< .001) ([Figure 4D](#F4){ref-type="fig"}); however, the male MCHR1 KO mice displayed similar discrimination index to the wild-type group (*P* \> .05) ([Figure 4D](#F4){ref-type="fig"}).

In the contextual fear conditioning assay, all groups barely exhibited freezing behavior (no difference between treatments, *P* \> .05; [Figure 4E](#F4){ref-type="fig"}) before the foot-shock stimulus during the training session. All groups exhibited a comparable increase in freezing behavior percentage immediately after the foot-shock stimulus (*P* \> .05). In the retention session, however, the male and female MCHR1 KO mice exhibited significantly lower freezing behavior compared with the corresponding wild-type groups (*P* \< .05, male, *P* \< .01, female) ([Figure 4E](#F4){ref-type="fig"}).

### Behavioral Responses in Mice With Conditional MCH Ablation {#s24}

The number of MCH immunoreactive neurons from each section was compared between DT-injected iDTR^+^/PmchCre^+^ (MCH cKO) mice and iDTR^+^/PmchCre^−^ littermates. Only animals that displayed over 90% loss of MCH neurons were included in the behavioral analyses ([Figure 5A--B](#F5){ref-type="fig"}).

![Behavioral phenotype of conditional ablation MCH neurons. (A) MCH immunoreactivity in the lateral hypothalamus of iDTR^+^/Cre^−^ and iDTR^+^/Cre^+^ mice following DT administration. (B) Counts of MCH immunoreactive neurons in DT-treated iDTR^+^/Cre^-^ and iDTR^+^/Cre^+^ mice. Unpaired *t* test (male: t = 13.67, *P* \< .0001, female: t = 10.72, *P* \< .0001), \*\*\**P* \< .0001. Data are presented as mean ± SEM. (C) Distance mice travelled in 60 minutes of locomotion test, unpaired student *t* test: male: t = 0.589, *P* = .567 (n = 6); female: t = 0.001, *P* = .99 (n = 8). Data are presented as mean ± SEM. (D) Number of marbles buried in 30 minutes: male: t = 2.27, *P* = .046 (n = 6), female: t = 0.3, *P* = .76. Unpaired student *t* test iDTR+/Cre- vs iDTR^+^/Cre^+^, \**P* \< .05 (n = 8). (E) Time mice spent interacting with empty cup and control mice in social interaction test: male: genotype effect, 2-way ANOVA, F~1,36~ = 0.039, *P* = .84. Bonferroni post hoc test: empty cup vs unfamiliar mouse, iDTR^+^/Cre^−^: t = 5.945, *P* \< .001, iDTR^+^/Cre^+^: t = 5.553, *P* \< .001 (n = 10); female: genotype effect, 2-way ANOVA, F~1,36~ = 0.5725, *P* = .45. Bonferroni post hoc test: empty cup vs unfamiliar mouse, iDTR^+^/Cre^−^: t = 5.702, *P* \< .001, iDTR^+^/Cre^+^: t = 3.634, *P* \< .001. \*\**P* \< .01, \*\*\**P* \< .001 (n = 12 and 8 for iDTR^+^/Cre^−^ and iDTR^+^/Cre^+^, respectively). Data are presented as mean ± SEM. (F) Prepulse inhibition ratio: male: 2-way ANOVA, genotype effect (F~1,54~ = 15.22, *P* = .0003), prepulse intensity effect (F~2,54~ = 9.049, *P* = .0004) followed by Bonferroni post hoc test: iDTR^+^/Cre^−^ vs iDTR^+^/Cre^+^, \**P* \< .05 (n = 7); female, 2-way ANOVA, genotype effect (F~1,39~ = 14.68, *P* = .0005), prepulse intensity effect (F~2,39~ =  11.23, *P* \< .0001). Bonferroni post hoc test: iDTR^+^/Cre^−^ vs iDTR^+^/Cre^+^, \**P* \< .05 (n = 8 and 7 for iDTR^+^/Cre^−^ and iDTR^+^/Cre^+^, respectively).](pyz051f0005){#F5}

Both male and female MCH cKO mice displayed normal locomotor activity ([Figure 5C](#F5){ref-type="fig"}) as well as normal social interaction (i.e., interacted more with an unfamiliar mouse than with an empty cup) ([Figure 5D](#F5){ref-type="fig"}). However, similar to the results of MCHR1 KO mice, male but not female MCH cKO mice showed increased repetitive behavior in the marble burying assay ([Figure 5E](#F5){ref-type="fig"}), and both male and female MCH cKO mice exhibited deficits in PPI ([Figure 5F](#F5){ref-type="fig"}).

Discussion {#s25}
==========

This study is the first to our knowledge to connect the downregulation of MCHR1 mRNA in the brains of schizophrenia patients to an eQTL, further providing a causal link between the germline MCHR1 deletion in mice and deficits in social behavior, sensorimotor gating, and multiple cognitive tasks that resemble schizophrenia symptoms. MCHR1 mRNA levels are significantly lower in the prefrontal cortex of subjects with schizophrenia using a large sample of 901 subjects. There is a widespread cortical expression of MCHR1 positive nuclei mainly in neurons and a strong increase of expression with postnatal development compared with prenatal expression; however, expression peaks in adolescence and significantly decreased during subsequent decades of life. There is also a decreased expression of MCHR1 in the PFC from female compared with male brains. The human developmental data suggest that the effect of PMCH on the cortex might be delayed until the MCH receptor begins to be more highly expressed during early postnatal development. Indeed, PMCH mRNA also occurs in very low levels prenatally until 10--12 days of postnatal life when a dramatic increase occurs, reaching its peak at the weaning time ([@CIT0009]). This increase in PMCH, which concurs with the crucial period of life that marks sucking-weaning transition, indicates a role for MCH system in the reorganization in neuronal processes that are involved in drinking and feeding behaviors at the weaning period.

Significant genetic evidence for the involvement of the MCHR1 locus in schizophrenia susceptibility came from the largest GWAS of SZ conducted to date ([@CIT0040]). The reduced MCHR1 expression in schizophrenia found in RNA-Seq analysis of DLPFC provides functional evidence that corroborates the genetic association results, raising the question whether MCHR1 SNPs may act as an expression quantitative trait loci (eQTLs), thus affecting the RNA expression of the receptor. A significant eQTL in exon 1 of the MCHR1 gene was found in a large expression database ([@CIT0021]), suggesting that minor allele carriers may indeed show reduced MCHR1 expression.

The MCH system has been implicated in modulating sleep, emotional behaviors, and learning and memory ([@CIT0032]; [@CIT0060]; [@CIT0001]). Since deficits in these functions are prominent in psychiatric disorders such as schizophrenia, depression, and autism, it is plausible to correlate the dysfunction of the MCH system with the pathophysiology of these disorders. While no study measured MCH in schizophrenia, MCH was measured in Alzheimer's patients and revealed elevated levels in the CSF compared with healthy persons. Interestingly, the CSF-MCH levels were found to correlate with T-tau and P-tau as well as to the severity of cognitive impairment in the Alzheimer's patients ([@CIT0053]). Consequently, we investigated whether the genetic deletion of MCHR1 and/or the conditional ablation of MCH neurons are associated with schizophrenic-like phenotype in mice. While it is difficult to recapitulate the human psychopathological phenotypes of schizophrenia in rodents, a number of behavioral patterns have been validated and historically accepted as translational models between rodents and humans. Locomotor hyperactivity, augmented stereotypic, and repetitive behaviors are widely used to evaluate the positive symptoms of schizophrenia ([@CIT0025]; [@CIT0020]; [@CIT0028]; [@CIT0035]; [@CIT0029]). The 3-chamber social behavior assay is used to model some negative symptoms in mice (social withdrawal) ([@CIT0034]).

The germline deletion of MCHR1 receptors significantly increased locomotor activity and stereotypic behavior in male and female mice in agreement with previous reports ([@CIT0030]; [@CIT0005]; [@CIT0051]). However, conditional ablation of MCH neurons in adult mice did not affect locomotor activity. The locomotor phenotype discrepancy between the 2 knockout models is interesting and could be explained by the actions of additional neurotransmitters co-expressed in MCH-neurons or might indicate differential roles of MCHR1 vs MCH during development.

Interestingly, the augmented repetitive behavior (as measured by marble burying) in male MCHR1 KO and MCH cKO mice that is in agreement with our recent report ([@CIT0051]) was not seen in female MCHR1 KO mice. The sex difference in the effect of MCH signaling deficits on repetitive behavior is of particular interest and points at a sexually dimorphic role for MCH signaling in schizophrenia. In humans, there was a significant decrease of MCHR1 expression in adult female cortex in both controls and patients with SZ. Evidence from anatomical, physiological, and pharmacological studies, in addition to human genetic studies, supports the dimorphic role of MCH in regulating various behaviors. Anatomical studies revealed a sexually dimorphic expression of MCH in rodent brain; MCH is expressed in the LH and medial zona incerta in both male and female animals, but only female rats express MCH in the latero-dorsal tegmental nucleus ([@CIT0043]), and only lactating dams express MCH in the preoptic area, the periventricular nucleus, and the anterior aspects of the paraventricular nucleus of the hypothalamus ([@CIT0024]; [@CIT0044]). The orexigenic effect of MCH has been demonstrated to be lower in female rats compared with male rats ([@CIT0052]), and there are sex differences in the response of MCH neurons to glucose ([@CIT0031]), which is attributed to the higher circulating levels of estradiol in females compared with males. In support of this view, estrogen was shown to decrease food intake and body weight through inhibiting MCH neurons ([@CIT0052]). MCHR1 genetic association with schizophrenia also seems to be sex-specific, with 6 SNPs found to be associated with schizophrenia in males but not females ([@CIT0055]; [@CIT0015]).

Abnormal social interaction and communication are the main features of the negative symptoms of schizophrenia ([@CIT0016]; [@CIT0036]; [@CIT0061]). Here, we found that germline deletion of MCHR1 but not ablation of MCH neurons affected social behavior in mice in the 3 chambers sociability test. Considering that in mice the essential role of olfaction in sociability, these results align well with our recent report that germline deletion of MCHR1 but not adult conditional ablation of MCH neurons produced deficits in olfaction functions ([@CIT0004]). We previously showed that disruption of the MCH system during developmental stage but not adulthood produced impairment in behaviors typically mediated by olfactory functions such as olfaction habituation/dishabituation and maternal behaviors, particularly pups retrieval and interaction with pups ([@CIT0002]; [@CIT0004]). Therefore, we propose that the neuronal circuit that includes innervations of olfactory structures by the MCH neurons is crucial for the integration of chemosensory signals throughout life, and this MCH-olfactory circuit plays a critical role in the development of social behavior during the early stages of life.

Cognitive deficits are commonly evaluated using a wide range of assays such as the novel object recognition (neutral memory), novel location recognition (spatial memory), and fear conditioning (emotional memory) ([@CIT0038]; [@CIT0037]; [@CIT0022]; [@CIT0010]). MCHR1 KO mice showed, to some extent, deficits in all cognitive assays tested. Both male and female MCHR1 KO mice displayed impairment in novel object recognition, an assay based on the tendency of rodents to explore a novel object more than a familiar one. On the other hand, in the novel location recognition assay, we found impairment in spatial memory in female MCHR1 KO mice, with a trend for impairment observed in male MCHR1 KO mice. Emotional memory, assessed by contextual fear conditioning test, was impaired in male and female MCHR1 KO mice. It could be claimed that locomotor hyperactivity seen in MCHR1 KO might mask the freezing behavior in the contextual fear conditioning test in these animals. However, this possibility is excluded given the comparable freezing scores displayed by MCHR1 KO and wild-type mice immediately after the foot-shock.

Impairment of prepulse inhibition of startle, which is present in patients with schizophrenia, reflects an inability to filter nonrelevant sensory information ([@CIT0057]). MCHR1 deletion and ablation of MCH neurons produced profound deficits in PPI, although the PPI deficits produced by germline deletion of MCHR1 were more pronounced in male than female mice. The congruent PPI deficit phenotypes in both MCH and MCHR1 knockout mouse models suggest that preattentive information processing is critically dependent on the intact functions of the MCH system.

CONCLUSION {#s26}
==========

MCH alterations affect many domains included in the Research Domain Criteria that overlap with schizophrenia (cognitive systems, social preferences, sensorimotor system) (<https://www.nimh.nih.gov/research/research-funded-by-nimh/rdoc/definitions-of-the-rdoc-domains-and-constructs.shtml>). The expression of MCHR1 is downregulated in the frontal cortex of patients with schizophrenia, decreased with age beginning in adults, and decreased in the female frontal cortex. The absence of intact MCH function in mice leads to behavioral deficits that mimic Research Domain Criteria constructs of schizophrenia including augmented repetitive behavior, social and cognitive deficits, and abnormal pre-attentive information. These results support prior work implicating the MCHR1 locus with schizophrenia susceptibility and connect the downregulation of MCHR1 mRNA in the brains of schizophrenia patients to an eQTL providing a potentially causal link to deficits in sensorimotor gating, social interaction, and multiple cognitive tasks in patients with schizophrenia.
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